IRB Handovers Harmonized In Eight-Fold Path Outlined By FDA, OHRP
This article was originally published in The Pink Sheet Daily
Executive Summary
Joint draft guidance on institutional review board switching for industry- and federal government-sponsored clinical trials advances the agencies’ goal creating umbrella coverage in human subject protection.